<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434902</url>
  </required_header>
  <id_info>
    <org_study_id>PO51082</org_study_id>
    <secondary_id>AOM-05037</secondary_id>
    <nct_id>NCT00434902</nct_id>
  </id_info>
  <brief_title>Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease</brief_title>
  <acronym>ETENDARD</acronym>
  <official_title>Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data show that pulmonary hypertension (PH), defined by a tricuspid regurgitation jet
      (TRJ) velocity &gt; or equal at 2.5m/s on Doppler echocardiography, is present in about 30% of
      adults with sickle cell disease (SCD) and is associated with poor prognosis. However in SCD
      the occurrence of PH (defined by mean pulmonary arterial pressure (mPAP)&gt; or equal at 25
      mmHg) is related to at least 3 mechanisms: PH due to hyperkinetic state with high cardiac
      output (CO) but normal pulmonary vascular resistance (PVR &lt;160 dynes), or postcapillary PH
      (pulmonary capillary wedge pressure PCWP &gt;15 mmHg), or precapillary pulmonary arterial
      hypertension (PAH) defined by mPAP &gt; or equal at 25 mmHg, PCWP&lt; or equal at 15 mmHg and PVR &gt;
      or equal at 160 dynes.The aim of this study is to evaluate in a French population of adults
      with sickle cell disease the characteristics, prevalence and prognosis of pulmonary
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive adult patients with sickle cell disease (SCD) had a Doppler echocardiography to
      evaluate if they had a suspected pulmonary hypertension (PH) on the basis of a tricuspid
      regurgitation jet (TRJ) velocity &gt; or equal at 2.5m/s. In this case, a right heart
      catheterization was performed to confirm or not this diagnosis and its mechanisms. Each
      included patient was followed every year for 3 years: during each visit, a clinical
      evaluation was obtained and a Doppler echocardiography. In case of emergence of a suspected
      PH, a right heart catheterization was performed to confirm or not this diagnosis and its
      mechanisms.

      Three groups of patients were defined: no PH, precapillary PH, and a third group including
      post-capillary PH and hyperkinetic state. These groups were well defined on the basis of the
      results of th Doppler echocardiography and right heart catheterisation.

      Characteristics of patients and their prognosis were evaluated in each group.

      In the same, way, biological study is planned to evaluate some biological markers of the
      mechanism of PH, and prognostic factors.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Sickle Cell Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Patients With Sickle Cell Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous SS sickle cell disease

          -  Male or female &gt; 18 years of age

          -  VOC (Vaso-Occlusive crisis) or ACS (Acute chest syndrome)within 6 weeks of inclusion
             (&quot;Stable state&quot;)

          -  Signed written Informed consent

        Exclusion Criteria:

          -  Creatinine clearance &lt; 30 ml/mn

          -  prothrombin ratio &lt; 50%

          -  Severe pneumopathy and TLC (Total lung capacity) &lt; 70%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald SIMONNEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Antoine Béclère, CLAMART</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Galacteros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Henri Mondor, Creteil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge ADNOT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Henri Mondor, CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard MAITRE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Henri Mondor, CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc HUMBERT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpîtal Antoine Béclere, CLAMART</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert GIROT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Tenon, PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François LIONNET, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital TENON, PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Françoise DRISS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Bicêtre, KREMLIN BICETRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier LAMBOTTE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Bicêtre, KREMLIN BICETRE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jocelyn INAMO, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Fort de France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gylna LOKO, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Fort de France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier SITBON, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Antoine Béclère, CLAMART</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Jaïs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Antoine Béclère, CLAMART</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anoosha Habibi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Henri Mondor, CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dora Bachir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Henri Mondor, CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent SAVALE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Henri Mondor, CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saadia Eddahibi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Henri Mondor, CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Garcia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Antoine Béclère, CLAMART</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. Review.</citation>
    <PMID>15194173</PMID>
  </reference>
  <reference>
    <citation>Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896-903. Erratum in: N Engl J Med 2002 Apr 18;346(16):1258.</citation>
    <PMID>11907289</PMID>
  </reference>
  <reference>
    <citation>Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004 Sep 30;351(14):1425-36. Review.</citation>
    <PMID>15459304</PMID>
  </reference>
  <reference>
    <citation>Lechapt E, Habibi A, Bachir D, Galacteros F, Schaeffer A, Desvaux D, Brochard L, Housset B, Godeau B, Maitre B. Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2003 Dec 1;168(11):1373-7. Epub 2003 Sep 11.</citation>
    <PMID>12969866</PMID>
  </reference>
  <reference>
    <citation>Maitre B, Habibi A, Roudot-Thoraval F, Bachir D, Belghiti DD, Galacteros F, Godeau B. Acute chest syndrome in adults with sickle cell disease. Chest. 2000 May;117(5):1386-92.</citation>
    <PMID>10807826</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2007</study_first_submitted>
  <study_first_submitted_qc>February 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2007</study_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Doppler Echocardiography</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Sickle cell disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

